Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RAUWOLFIA SERPENTINA vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Rauwolfia serpentina alkaloids (e.g., reserpine) deplete catecholamines and serotonin from central and peripheral neurons by binding irreversibly to vesicular monoamine transporters (VMAT), leading to reduced sympathetic outflow and decreased blood pressure.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Hypertension,Management of agitated psychotic states (historical use)
Hypertension
Oral: 50–100 mg twice daily for 2 weeks, then maintenance of 50–100 mg once daily.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
Terminal elimination half-life: 40-100 hours (mean ~70 h). Accumulation occurs with chronic dosing; steady-state reached in ~2-3 weeks.
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Hepatic metabolism via CYP450 enzymes, with active metabolites (e.g., reserpine is metabolized by hydrolysis and conjugation); significant first-pass effect.
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Renal (urinary) elimination of unchanged drug and metabolites: approximately 60-70% as metabolites, <1% unchanged. Fecal excretion: 30-40% via bile.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Plasma protein binding: approximately 80-90%, primarily to alpha1-acid glycoprotein and albumin.
~90%, primarily to albumin
Vd: 0.5-1.0 L/kg. High tissue distribution, especially to adipose tissue and brain, correlating with extensive accumulation.
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Oral bioavailability: approximately 50% (range 30-60%) due to first-pass metabolism. Not administered parenterally in clinical practice.
Oral: 50–60% (extensive first-pass metabolism)
Not studied; avoid use in severe renal impairment (GFR <30 m L/min) due to risk of accumulation and CNS effects.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
Contraindicated in severe hepatic impairment (Child-Pugh class C). Use with caution in Child-Pugh A/B; consider 50% dose reduction.
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
Not recommended in children <12 years. For ages ≥12: 100 µg/kg twice daily, max 50 mg/dose.
Not recommended for pediatric use; safety in children under 12 years not established.
Start at lowest dose (50 mg once daily) and titrate slowly; monitor for CNS depression, orthostatic hypotension, and depression.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
None
None
Risk of severe depression and suicide; use with caution in patients with history of depression. May cause bradycardia, electrolyte disturbances, and gastrointestinal bleeding. Avoid abrupt discontinuation to prevent withdrawal symptoms. Possible extrapyramidal symptoms and parkinsonism.
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
Active peptic ulcer, ulcerative colitis, history of depression (especially with suicidal tendencies), electroconvulsive therapy, pheochromocytoma, and concomitant MAO inhibitors.
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
Avoid tyramine-rich foods (aged cheeses, cured meats, fermented products) as Rauwolfia may potentiate pressor effects. Limit alcohol intake. No specific food restrictions otherwise; but taking with food may reduce gastrointestinal upset.
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
Rauwolfia serpentina (reserpine) is Pregnancy Category C. First trimester: Limited human data; animal studies show increased fetal resorptions and skeletal anomalies. Second/third trimesters: May cause neonatal bradycardia, hypotonia, and nasal congestion due to placental transfer. Use only if benefit outweighs risk.
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
Rauwolfia alkaloids (reserpine) are excreted into breast milk. M/P ratio is not established. Avoid breastfeeding due to potential for infant hypotension, bradycardia, and extrapyramidal effects. Alternative therapy recommended.
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
No specific dose adjustments are established; however, pharmacokinetics may be altered due to increased plasma volume and renal clearance. Use lowest effective dose and monitor maternal response closely.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
1. Rauwolfia serpentina (reserpine) depletes catecholamines and serotonin from central and peripheral nerve endings; onset of action is slow (weeks) and offset prolonged. 2. Use cautiously in patients with history of peptic ulcer disease due to increased gastric acid secretion. 3. May cause significant bradycardia and orthostatic hypotension; monitor blood pressure and heart rate regularly. 4. Avoid concomitant use with MAOIs, tricyclic antidepressants, or sympathomimetics due to risk of hypertensive crisis. 5. Documented nasal congestion and sedation are common; consider alternative antihypertensives if tolerated poorly.
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
Take exactly as prescribed; do not stop suddenly as this may cause rapid rise in blood pressure.,Rise slowly from sitting or lying down to minimize dizziness from low blood pressure.,Avoid alcohol, which can worsen dizziness and drowsiness.,Report persistent nasal congestion, stomach pain, or unusual tiredness to your doctor.,Use caution when driving or operating machinery until you know how this medication affects you.
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RAUWOLFIA SERPENTINA vs ALDORIL 15, answered by our medical review team.
RAUWOLFIA SERPENTINA is a Antihypertensive that works by Rauwolfia serpentina alkaloids (e.g., reserpine) deplete catecholamines and serotonin from central and peripheral neurons by binding irreversibly to vesicular monoamine transporters (VMAT), leading to reduced sympathetic outflow and decreased blood pressure.. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RAUWOLFIA SERPENTINA and ALDORIL 15 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RAUWOLFIA SERPENTINA is: Oral: 50–100 mg twice daily for 2 weeks, then maintenance of 50–100 mg once daily.. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RAUWOLFIA SERPENTINA and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RAUWOLFIA SERPENTINA is classified as Category C. Rauwolfia serpentina (reserpine) is Pregnancy Category C. First trimester: Limited human data; animal studies show increased fetal resorptions and skeletal anomalies. Second/third . ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.